Our Team
Underpinned by leading management, extensive experience and industry validation
What we do
Mental health is one of the largest healthcare issues globally. The WHO estimate that nearly a billion people live with a mental health disorder, with anxiety and depression being the most common. At TrivarX, we believe that an objective measure of mental health is key to helping address this.
Our technology analyses the electrical signals from the brain and the heart to identify mental illness. Our lead product, MEB-001 analyses the data from a standard sleep study to identify depression at a sensitivity of over 85%, compared to the standard of care which is only 46% accurate.
Management Team
Dr. Archie Defillo
Chief Medical Officer
- 25 years clinical experience with neurological diseases and a trained neurosurgeon
- 70+ publications on topics predominantly based on heart rate studies
- Dedicated to advancing TRI’s knowledge of heart rate variability and autonomic modulation.
Kai Sun
Chief Operating Officer
- Mr Sun drives the company’s mission to innovate the connection between biological markers and mental health conditions
- Previously, he scaled one of the largest corporate health and fitness platforms in Australia and holds a Bachelors of Laws and Commerce from the University of Western Australia.
Dr. Massimiliano Grassi
Head of Artificial Intelligence
- 15 years experience as a data scientist in mental health field with an extensive background in psychology
- Ph. D in Supervised Machine Learning for Clinical Psychiatry
- Focused on the development of machine learning algorithms using sleep as the window into mental health.
Board of Directors
David Trimboli
Non-executive Chairman
Mr Trimboli is an experienced global investor with experience in commodities financing and trading. He has undertaken investments activities and hold diverse interests in commodities, industrial minerals, real estate and technology and mental health in Australia and internationally.
Mr Trimboli is the founder of Seefeld Investments with offices in London, Zug and Perth. He has formerly a long serving senior coal trader at the world’s largest commodities trading group, Glencore International AG and was a key member of the Glencore team when the group successfully completed its IPO in London and Hong Kong.
He currently holds a Managing Director position in Seefeld Investments Pty Ltd, Non-Executive Chairman in Audeara Limited (ASX: AUA) and Non-Executive Director positions in the following Companies Quantum Graphite Limited (ASX: QGL), TradeMutt, Yumm Confectionar, The Reading Switch, Carecircle and Greater Outcomes, all being companies in revenue generating businesses with developed management teams and on pathways to profitability.
Dr Tony Keating
Executive Director
Dr Keating was the co-founder and Chief Executive Officer of ResApp Health, a digital health company which successfully developed a groundbreaking smartphone technology for accurately diagnosing respiratory diseases based on cough analysis.
Dr Keating led the ResApp team through the commercialisation of the company’s technology, commencing with a successful R&D phase through to global regulatory approvals and commercial partnerships, before overseeing the sale of the company to Pfizer in 2022 for $180m. Following the acquisition, he transitioned to the role of Vice President at Pfizer to manage the integration of ResApp’s business.
Prior to co-founding ResApp, Dr Keating was the Director of Commercial Engagement at UniQuest, the commercialisation arm of The University of Queensland (UQ) which specialises in industry university collaborations for the UQ’s in-house network of 7,000 world-class researchers. Dr Keating holds a PhD in Mechanical Engineering from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.
Chris Ntoumenopoulos
Non-executive Director
Mr Ntoumenopoulos holds the position as a Director at Tryp Therapeutics. He has a background as the former Managing Director at 21 Corporate, an Australian corporate advisory firm. He is also a seasoned entrepreneur on the lookout for innovative and groundbreaking technologies and businesses.
With over 20 years of experience in the financial sector, Mr Ntoumenopoulos has a strong track record in raising capital and providing corporate advice. He was also a founding director of ResApp Health, which Pfizer and Race Oncology later acquired.
Mr Ntoumenopoulos holds a Bachelor of Commerce degree from the University of Western Australia, focusing on Money and Banking, Investment Finance, and Electronic Commerce.